Piflufolastat F-18 ( 18 F-DCFPyL) for PSMA PET imaging in prostate cancer .
Andrew F VoterRudolf A WernerKenneth J PientaMichael A GorinMartin G PomperLilja B SolnesSteven P RowePublished in: Expert review of anticancer therapy (2022)
F-DCFPyL over conventional imaging modalities for the staging and restaging of prostate cancer. The remarkable diagnostic accuracy of PSMA-PET is reshaping prostate cancer imaging and the modularity of these agents hint at exciting new diagnostic and therapeutic opportunities that have the potential to improve the care of patients with prostate cancer as a whole. .